论文部分内容阅读
目的观察大剂量国产胸腺肽对慢性活动性乙肝患者血清细胞因子的影响，探讨胸腺肽治疗慢性乙肝的机制。方法选择慢性活动性乙肝患者34例，分成两组：胸腺肽组19例，一般护肝组15例。比较观察治疗前后患者血清IFN—α、sIL－2r、TNF，和β2－MG为指标的变化。结果胸腺肽治疗后，患者PBMIFN—α诱生能力较治疗前上升119．99％，血清sIL—2r和TNF含量分别下降了35．56％和41．80％，治疗初期对β2—MG有提升作用。一般护肝组对慢性乙肝患者PBMIFN－α诱生能力和下调血清sIL-2r、TNF的作用弱于胸腺肽，对β2—MG指标没有影响。结论胸腺肽治疗慢性乙肝疗效与促进IFN产生和下调sIL-2r和TNF等多项免疫调节功能有关。
Objective To observe the effects of high-dose domestic thymosin on serum cytokines in patients with chronic active hepatitis B and to explore the mechanism of thymosin in treating chronic hepatitis B patients. Methods 34 patients with chronic active hepatitis B were selected and divided into two groups: 19 for thymosin group and 15 for general liver protection group. The changes of serum IFN-α, sIL-2r, TNF, and β2-MG were observed before and after treatment. Results Thymosin treatment induced a significant increase in PBMIFN-α-induced abilities of 119.99% and 35.56% and 41.80%, respectively, and increased the level of β2-MG in the early stage of treatment . General liver protection group of chronic hepatitis B patients PBMIFN-α induced ability and decreased serum sIL-2r, TNF less weaker than thymosin, β2-MG indicators had no effect. Conclusions The therapeutic effect of thymosin on chronic hepatitis B is related to the promotion of IFN production and down-regulation of multiple immunoregulatory functions such as sIL-2r and TNF.